{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:19:43Z","timestamp":1788369583140,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>Patients with isolated rapid-eye-movement sleep behavior disorder (iRBD) have an increased risk of developing neurodegenerative diseases. This study assessed cerebrospinal-fluid (CSF) biomarkers of neurodegeneration and blood-brain barrier (BBB) alteration in patients with iRBD compared to controls and ascertain whether these biomarkers may predict phenoconversion to alpha-synucleinopathies (Parkinson\u2019s Disease (PD), Dementia with Lewy bodies (DLB), Multiple System Atrophy (MSA)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients and controls underwent between 2012 and 2016 a neurological assessment, a lumbar puncture for CSF biomarker analysis (\u03b2-amyloid42 - A\u03b242; total-tau, and phosphorylated tau), and BBB alteration (CSF\/serum albumin ratio). All patients with iRBD were followed until 2021 and then classified into patients who converted to alpha-synucleinopathies (iRBD converters, cRBD) or not (iRBD non-converters, ncRBD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four patients with iRBD (mean age 67.12\u2005\u00b1\u20058.14) and 33 controls (mean age 64.97\u2005\u00b1\u20058.91) were included. At follow-up (7.63\u2005\u00b1\u20053.40 years), eight patients were ncRBD and 33 patients were cRBD: eleven converted to PD, 10 to DLB, and two to MSA. Patients with iRBD showed lower CSF A\u03b242 levels and higher CSF\/serum albumin ratio than controls. Cox regression analysis showed that the phenoconversion rate increases with higher motor impairment (hazard ratio [HR]\u2005=\u20051.23, p\u2005=\u20050.032). CSF A\u03b242 levels predicted phenoconversion to DLB (HR\u2005=\u20050.67, p\u2005=\u20050.038) and BBB alteration predicted phenoconversion to PD (HR\u2005=\u20051.20, p\u2005=\u20050.038).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study showed that low CSF A\u03b242 levels and high BBB alteration may predict the phenoconversion to DLB and PD in patients with iRBD, respectively. These findings highlight the possibility to discriminate phenoconversion in iRBD patients through CSF biomarkers; however, further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsad198","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T15:14:50Z","timestamp":1691248490000},"source":"Crossref","is-referenced-by-count":15,"title":["Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder"],"prefix":"10.1093","volume":"47","author":[{"given":"Mariana","family":"Fernandes","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Maio","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"},{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0715-6396","authenticated-orcid":false,"given":"Paolo","family":"Eusebi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Neurology Clinic, University Hospital of Perugia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Placidi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"},{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Izzi","sequence":"additional","affiliation":[{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Spanetta","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"De Masi","sequence":"additional","affiliation":[{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Lupo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Calvello","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Nuccetelli","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Molecular Biology, University of Rome \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Molecular Biology, University of Rome \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"},{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u201d , Rome , Italy"},{"name":"Sleep Medicine Centre, Neurology Unit, University Hospital \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"2024051516512110000_CIT0001","author":"American Academy of Sleep Medicine","year":"2014"},{"key":"2024051516512110000_CIT0002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/978-1-4939-6578-6_27","article-title":"International classification of sleep disorders","volume-title":"Sleep Disorders Medicine.","author":"Thorpy","year":"2017"},{"issue":"15","key":"2024051516512110000_CIT0003","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1212\/01.wnl.0000340980.19702.6e","article-title":"Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder","volume":"72","author":"Postuma","year":"2009","journal-title":"Neurology."},{"issue":"8","key":"2024051516512110000_CIT0004","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.sleep.2012.10.009","article-title":"Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series","volume":"14","author":"Schenck","year":"2013","journal-title":"Sleep Med."},{"issue":"15","key":"2024051516512110000_CIT0005","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/mds.22757","article-title":"Idiopathic REM sleep behavior disorder in the transition to degenerative disease","volume":"24","author":"Postuma","year":"2009","journal-title":"Mov Disord."},{"issue":"2","key":"2024051516512110000_CIT0006","doi-asserted-by":"crossref","first-page":"e89741","DOI":"10.1371\/journal.pone.0089741","article-title":"Neurodegenerative disorder risk in idiopathic rem sleep behavior disorder: study in 174 patients. Toft M, ed","volume":"9","author":"Iranzo","year":"2014","journal-title":"PLoS One."},{"issue":"7","key":"2024051516512110000_CIT0007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1474-4422(06)70476-8","article-title":"Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study","volume":"5","author":"Iranzo","year":"2006","journal-title":"Lancet Neurol."},{"issue":"1","key":"2024051516512110000_CIT0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-015-0279-9","article-title":"Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis","volume":"25","author":"Palma","year":"2015","journal-title":"Clin Auton Res."},{"issue":"5","key":"2024051516512110000_CIT0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson\u2019s disease: pre-Motor disorders in Parkinson\u2019s disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov Disord."},{"issue":"3","key":"2024051516512110000_CIT0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain."},{"issue":"3","key":"2024051516512110000_CIT0011","first-page":"1","article-title":"CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD","volume":"19","author":"Liguori","year":"2019","journal-title":"Curr Neurol Neurosci Rep."},{"key":"2024051516512110000_CIT0012","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2021","journal-title":"Brain."},{"issue":"3","key":"2024051516512110000_CIT0013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol."},{"key":"2024051516512110000_CIT0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cca.2019.04.078","article-title":"Parkinson\u2019s and Lewy body dementia CSF biomarkers","volume":"495","author":"Parnetti","year":"2019","journal-title":"Clin Chim Acta."},{"issue":"1","key":"2024051516512110000_CIT0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-130995","article-title":"Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson\u2019s disease, and Alzheimer\u2019s disease","volume":"38","author":"Kaerst","year":"2014","journal-title":"J Alzheimers Dis."},{"issue":"12","key":"2024051516512110000_CIT0016","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology."},{"issue":"15","key":"2024051516512110000_CIT0017","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson\u2019s disease","volume":"24","author":"Compta","year":"2009","journal-title":"Mov Disord."},{"issue":"8","key":"2024051516512110000_CIT0018","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov Disord."},{"issue":"10","key":"2024051516512110000_CIT0019","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","article-title":"Cerebrospinal fluid biomarkers in parkinson\u2019s disease with dementia and dementia with Lewy bodies","volume":"64","author":"Parnetti","year":"2008","journal-title":"Biol Psychiatry."},{"issue":"12","key":"2024051516512110000_CIT0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord."},{"issue":"5","key":"2024051516512110000_CIT0021","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid-\u03b2-peptides in Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain."},{"key":"2024051516512110000_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2014.00053","article-title":"Differential role of CSF alpha-synuclein species, tau, and A\u03b242 in Parkinson\u2019s disease","volume":"6","author":"Parnetti","year":"2014","journal-title":"Front Aging Neurosci."},{"issue":"10","key":"2024051516512110000_CIT0023","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","article-title":"REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease","volume":"91","author":"Pagano","year":"2018","journal-title":"Neurology."},{"key":"2024051516512110000_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2020.00185","article-title":"Dysfunction of the blood-brain barrier\u2014a key step in neurodegeneration and dementia","volume":"12","author":"Noe","year":"2020","journal-title":"Front Aging Neurosci."},{"key":"2024051516512110000_CIT0025","first-page":"413","article-title":"The Impact of Neurovascular, Blood-Brain Barrier, and Glymphatic Dysfunction in Neurodegenerative and Metabolic Diseases","volume-title":"Int Rev Neurobiol.","author":"Braun","year":"2020"},{"issue":"1","key":"2024051516512110000_CIT0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol Rev."},{"issue":"3","key":"2024051516512110000_CIT0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1871527316666161205123123","article-title":"Cerebrospinal-fluid Alzheimer\u2019s disease biomarkers and blood-brain barrier integrity in a natural population of cognitive intact parkinson\u2019s disease patients","volume":"16","author":"Liguori","year":"2016","journal-title":"CNS Neurol Disord - Drug Targets."},{"issue":"1","key":"2024051516512110000_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-188","article-title":"Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson\u2019s disease","volume":"9","author":"Pisani","year":"2012","journal-title":"J Neuroinflammation."},{"issue":"2","key":"2024051516512110000_CIT0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3233\/JAD-200168","article-title":"Cerebrospinal fluid\/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias","volume":"75","author":"Musaeus","year":"2020","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"3","key":"2024051516512110000_CIT0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord."},{"issue":"12","key":"2024051516512110000_CIT0031","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord."},{"issue":"1","key":"2024051516512110000_CIT0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"issue":"9","key":"2024051516512110000_CIT0033","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology."},{"issue":"10","key":"2024051516512110000_CIT0034","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","article-title":"Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions","volume":"85","author":"Magdalinou","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"2024051516512110000_CIT0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","article-title":"The cerebrospinal fluid \u201calzheimer profile\u201d: easily said, but what does it mean","volume":"10","author":"Duits","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"2024051516512110000_CIT0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.sleep.2019.01.003","article-title":"Obstructive sleep apnea may induce orexinergic system and cerebral \u03b2-amyloid metabolism dysregulation: is it a further proof for Alzheimer\u2019s disease risk","volume":"56","author":"Liguori","year":"2019","journal-title":"Sleep Med."},{"issue":"3","key":"2024051516512110000_CIT0037","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol."},{"issue":"2","key":"2024051516512110000_CIT0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","article-title":"Amyloid-\u03b2(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease","volume":"56","author":"Mulder","year":"2010","journal-title":"Clin Chem."},{"issue":"2","key":"2024051516512110000_CIT0039","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191124","article-title":"Sleep-wake cycle in Alzheimer\u2019s disease is associated with tau pathology and orexin dysregulation. Ferini-Strambi L, ed","volume":"74","author":"Liguori","year":"2020","journal-title":"J Alzheimers Dis."},{"issue":"2","key":"2024051516512110000_CIT0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.expneurol.2009.07.028","article-title":"A\u03b21-42 detection in CSF of Alzheimer\u2019s disease is influenced by temperature: indication of reversible A\u03b21-42 aggregation","volume":"223","author":"Sancesario","year":"2010","journal-title":"Exp Neurol."},{"issue":"10","key":"2024051516512110000_CIT0041","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1007\/s00415-022-11182-z","article-title":"18F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment","volume":"269","author":"Fernandes","year":"2022","journal-title":"J Neurol."},{"key":"2024051516512110000_CIT0042","volume-title":"SPSS - Statistical Package for Social Sciences","author":"IBM","year":"2020"},{"key":"2024051516512110000_CIT0043","author":"Team RC","year":"2016"},{"issue":"1","key":"2024051516512110000_CIT0044","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrneurol.2017.157","article-title":"Idiopathic REM sleep behaviour disorder and neurodegeneration - an update","volume":"14","author":"H\u00f6gl","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"8","key":"2024051516512110000_CIT0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol."},{"issue":"12","key":"2024051516512110000_CIT0046","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.1212\/WNL.0000000000005166","article-title":"CSF tau and \u03b2-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders","volume":"90","author":"Irwin","year":"2018","journal-title":"Neurology."},{"issue":"9","key":"2024051516512110000_CIT0047","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1212\/WNL.54.9.1875","article-title":"Decreased CSF amyloid \u03b242 and normal tau levels in dementia with Lewy bodies","volume":"54","author":"Kanemaru","year":"2000","journal-title":"Neurology."},{"issue":"2","key":"2024051516512110000_CIT0048","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10072-022-06530-w","article-title":"Cerebrospinal fluid\/serum albumin quotient (Q-Alb) is not increased in Alzheimer\u2019s disease compared to neurological disease controls: a retrospective study on 276 patients","volume":"44","author":"Giacopuzzi Grigoli","year":"2022","journal-title":"Neurol Sci."},{"key":"2024051516512110000_CIT0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med Rev."},{"issue":"7","key":"2024051516512110000_CIT0050","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/brain\/awz111","article-title":"Evolution of prodromal Parkinson\u2019s disease and dementia with Lewy bodies: a prospective study","volume":"142","author":"Fereshtehnejad","year":"2019","journal-title":"Brain."},{"issue":"3","key":"2024051516512110000_CIT0051","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"15","key":"2024051516512110000_CIT0052","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/mds.23287","article-title":"CSF A\u03b2(42) and tau in Parkinson\u2019s disease with cognitive impairment","volume":"25","author":"Montine","year":"2010","journal-title":"Mov Disord."},{"issue":"8","key":"2024051516512110000_CIT0053","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid Tau\/\u03b1-synuclein ratio in Parkinson\u2019s disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Mov Disord."},{"issue":"1","key":"2024051516512110000_CIT0054","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2011.08.012","article-title":"Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes","volume":"18","author":"Bech","year":"2012","journal-title":"Parkinsonism Relat Disord."},{"issue":"8","key":"2024051516512110000_CIT0055","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1212\/WNL.0000000000011454","article-title":"\u03b2-Amyloid PET and 123I-FP-CIT SPECT in mild cognitive impairment at risk for lewy body dementia","volume":"96","author":"Chen","year":"2021","journal-title":"Neurology."},{"issue":"8","key":"2024051516512110000_CIT0056","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.25048","article-title":"Brain amyloid and cognition in Lewy body diseases","volume":"27","author":"Gomperts","year":"2012","journal-title":"Mov Disord."},{"issue":"3","key":"2024051516512110000_CIT0057","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.jnen.0000205145.54457.ea","article-title":"Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies","volume":"65","author":"Deramecourt","year":"2006","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"2024051516512110000_CIT0058","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric- and total-\u03b1-synuclein in premotor, motor and dementia stages of Parkinson\u2019s disease","volume":"262","author":"Compta","year":"2015","journal-title":"J Neurol."},{"issue":"4","key":"2024051516512110000_CIT0059","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3233\/JPD-202243","article-title":"Predictors of conversion to \u03b1-synucleinopathy diseases in idiopathic rapid eye movement sleep behavior disorder","volume":"10","author":"Ye","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2024051516512110000_CIT0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/acn3.51269","article-title":"Dopamine transporter imaging predicts clinically-defined \u03b1-synucleinopathy in REM sleep behavior disorder","volume":"8","author":"Chahine","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"2024051516512110000_CIT0061","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.sleep.2022.08.018","article-title":"Neuropsychiatric, neuropsychological, and neuroimaging features in isolated REM sleep behavior disorder: the importance of MCI","volume":"100","author":"Vacca","year":"2022","journal-title":"Sleep Med."}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsad198\/51058194\/zsad198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/47\/1\/zsad198\/57678498\/zsad198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/47\/1\/zsad198\/57678498\/zsad198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:52:05Z","timestamp":1715777525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsad198\/7237865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,5]]},"published-print":{"date-parts":[[2024,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsad198","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,8,5]]},"article-number":"zsad198"}}